Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks-Reference-Cited by-同舟云学术

Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks

Published:2017-01-05 Issue:1 Volume:12 Page:e0169631
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Suresh Manasa,Korolowicz Kyle E.,Balarezo Maria,Iyer Radhakrishnan P.,Padmanabhan Seetharamaiyer,Cleary Dillon,Gimi Rayomand,Sheri Anjaneyulu,Yon Changsuek,Kallakury Bhaskar V.,Tucker Robin D.,Afdhal Nezam,Menne Stephan^ORCID

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures;D Lavanchy;J Viral Hepat,2004

2. Hepatitis B virus: pathogenesis, viral intermediates, and viral replication;JY Lee;Clin Liver Dis,2004

3. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013;A Schweitzer;Lancet,2015

4. Hepatitis B therapy;H Kwon;Nat Rev Gastroenterol Hepatol,2011

5. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways;Y Liu;J Virol,2015

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of a potent and specific retinoic acid-inducible gene 1 pathway activator as a Hepatitis B Virus antiviral through a novel cell-based reporter assay;Journal of Virological Methods;2024-04

2. Transcriptome-wide association studies associated with Crohn’s disease: challenges and perspectives;Cell & Bioscience;2024-02-25

3. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments;Expert Review of Gastroenterology & Hepatology;2023-10-17

4. Developments in pharmacotherapeutic agents for hepatitis B – how close are we to a functional cure?;Expert Opinion on Pharmacotherapy;2023-05-15

5. A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B;Liver International;2022-11-11